RELATIONSHIP BETWEEN PERSONALITY AND DEBRISOQUINE HYDROXYLATION CAPACITY - SUGGESTION OF AN ENDOGENOUS NEUROACTIVE SUBSTRATE OR PRODUCT OF THE CYTOCHROME-P4502D6

被引:140
作者
LLERENA, A
EDMAN, G
COBALEDA, J
BENITEZ, J
SCHALLING, D
BERTILSSON, L
机构
[1] KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN PHARMACOL,S-14186 HUDDINGE,SWEDEN
[2] KAROLINSKA INST,KAROLINSKA HOSP,DEPT PSYCHIAT & PSYCHOL,S-14186 HUDDINGE,SWEDEN
[3] UNIV EXTREMADURA,DEPT PHARMACOL & PSYCHIAT,BADAJOZ,SPAIN
关键词
PHARMACOGENETICS; DEBRISOQUINE; PERSONALITY;
D O I
10.1111/j.1600-0447.1993.tb03325.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
We administered the Karolinska Scales of Personality to 225 healthy subjects in Spain selected from a group of 925 individuals previously phenotyped with regard to their capacity to hydroxylate debrisoquine. A significant relationship was found between the scores in as many as 4 of the 15 subscales (psychic anxiety, psychasthenia, inhibition of aggression and, socialization) and the debrisoquine hydroxylation capacity. Poor metabolizers were more anxiety-prone and less successfully socialized than extensive metabolizers of debrisoquine. This and a previous study among subjects in Sweden suggest that there may be a relationship between personality and the activity of the enzyme hydroxylating debrisoquine (cytochrome P4502D6). This polymorphic enzyme may have an endogenous neuroactive substrate or product, such as a biogenic neurotransmitter amine.
引用
收藏
页码:23 / 28
页数:6
相关论文
共 30 条
[1]   MUTANT DEBRISOQUINE HYDROXYLATION GENES IN PARKINSONS-DISEASE [J].
ARMSTRONG, M ;
DALY, AK ;
CHOLERTON, S ;
BATEMAN, DN ;
IDLE, JR .
LANCET, 1992, 339 (8800) :1017-1018
[2]   METABOLIC OXIDATION PHENOTYPES AS MARKERS FOR SUSCEPTIBILITY TO LUNG-CANCER [J].
AYESH, R ;
IDLE, JR ;
RITCHIE, JC ;
CROTHERS, MJ ;
HETZEL, MR .
NATURE, 1984, 312 (5990) :169-170
[3]  
BARBEAU A, 1985, LANCET, V2, P1213
[4]   DEBRISOQUIN OXIDATION POLYMORPHISM IN A SPANISH POPULATION [J].
BENITEZ, J ;
LLERENA, A ;
COBALEDA, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (01) :74-77
[5]  
BENITEZ J, 1988, CLIN PHARMACOL THER, V85, P44
[6]  
BERTILSSON L, 1989, LANCET, V2, P555
[7]  
BERTILSSON L, 1991, CURRENT PRACTICES FU, P73
[8]  
BROSEN K, IN PRESS PSYCHOPHARM
[9]   CHROMOSOMAL ASSIGNMENT OF HUMAN CYTOCHROME-P-450 (DEBRISOQUINE SPARTEINE TYPE) TO CHROMOSOME 22 [J].
EICHELBAUM, M ;
BAUR, MP ;
DENGLER, HJ ;
OSIKOWSKAEVERS, BO ;
TIEVES, G ;
ZEKORN, C ;
RITTNER, C .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 23 (04) :455-458
[10]   A FAMILY AND POPULATION STUDY OF THE GENETIC-POLYMORPHISM OF DEBRISOQUINE OXIDATION IN A WHITE BRITISH-POPULATION [J].
EVANS, DAP ;
MAHGOUB, A ;
SLOAN, TP ;
IDLE, JR ;
SMITH, RL .
JOURNAL OF MEDICAL GENETICS, 1980, 17 (02) :102-105